華昌達(300278.SZ):高新投集團成為公司持股5%以上股東
格隆匯 2 月 3日丨華昌達(300278.SZ)公佈,公司今日收到深圳市高新投集團有限公司(“高新投集團”)出具的《簡式權益變動報吿書》。
持股5%以上股東顏華持有的660萬股無限售流通股及2400萬股首發後限售股已競拍成功,上述股份競得者分別為深圳市高新投保證擔保有限公司(“高新投擔保”)及高新投集團。由於高新投擔保為高新投集團全資子公司,為同一控制,二者構成一致行動關係,高新投集團為信息披露義務人,其直接持有及通過全資子公司高新投擔保間接持有華昌達股份總數為3060萬股,佔公司總股本的5.12%,成為公司持股5%以上股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.